Search filters
Filters
Clear All

Phase

  • 12
  • 39
  • 2
  • 26
  • 1
  • 16
  • 1
  • 251
  • 352
  • 262
  • 4
  • 25
  • 323

Found 352 oncology trials

A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 25420: Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release

99 years or below
All genders
This study is available to subjects who have previously agreed to receive lisocabtagene maraleucel. The lisocabtagene maraleucel T cells for those subjects that were produced do not meet all of the prespecified release criteria to be used as a routine prescription drug as required by the governing health authority-- this …
Learn More

UPCC 31420: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stag

99 years or below
All genders
This is a double-blind, randomized, multicenter international Phase 3 study of CAEL-101 combined with standard of care plasma cell dyscrasia (PCD) treatment versus placebo combined with standard of care PCD treatment in Mayo stage IIIa PCD treatment-naïve AL amyloidosis patients. T
Learn More

UPCC 05424: Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis

99 years or below
All genders
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section3 (Objectives and Endpoints). Please refer to Protocol Section3 (Objectives and Endpoints).
Learn More

UPCC 35423 Fitness-adapted, pembrolizumab-based therapy for untreated classical Hodgkin lymphoma patients 60 years of age and above (cHL 001)

99 years or below
All genders
Please refer to Protocol Section 3.1 (Primary Objectives, Endpoints & Hypotheses). Please refer to Protocol Section 3.1 Primary Objectives, Endpoints & Hypotheses. Please refer to Protocol Section 3.2 (Secondary Objectives and Endpoints).
Learn More

UPCC 25223: A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants with Advanced/Recurrent HEpatocellular CarciNomA

99 years or below
All genders
Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands). Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands). Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands).
Learn More

UPCC 05423 A Phase I, Open-Label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ONO-7018 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leuk

99 years or below
All genders
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Learn More

UPCC 04424 A Phase 1 FirstinHuman Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV787 in Adult Subjects with Acute Myeloid Leukemia (AML)

99 years or below
All genders
Please refer to Protocol Section1.1.1 (Objectives and Endpoints). Please refer to Protocol Section1.1.1 (Objectives and Endpoints). Please refer to Protocol Section1.1.1 (Objectives and Endpoints).
Learn More

CAB-101: A phase 1, open-label, safety and dosing study of autologous desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in subjects with active, anti-DSG3, mucosal-dominant pemphigus vulgaris

99 years or below
All genders
This research is being done to determine the maximum dose of an investigational drug called autologous desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) that can be safely given to patients with pemphigus vulgaris to target and kill only the B cells that are making the autoantibodies that attack DSG3.
Learn More

UPCC 19424: A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in P

99 years or below
All genders
Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands). Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands). Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands).
Learn More

UPCC 13824: A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma

99 years or below
All genders
The primary objective of the study is to compare V940 plus pembrolizumab to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator. The primary hypothesis is that V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS. We would like to rely …
Learn More
311 - 320 of 352